Fluvoxamine augmentation of olanzapine in chronic schizophrenia: Pharmacokinetic interactions and clinical effects

Journal of Clinical Psychopharmacology

Volumn 22, Issue 5, 2002, Pages 502-506

  Hiemke, Christoph ^a   Peled, Avi ^a   Jabarin, Mahmoud ^a   Hadjez, Jack ^a   Weigmann, Harald ^a   Härtter, Sebastian ^a   Modai, Ilan ^a   Ritsner, Michael ^a   Silver, Henry ^a  

^a SHA'AR MENASHE MENTAL HEALTH CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CLOZAPINE; CYTOCHROME P450 1A2; DRUG METABOLITE; FLUOXETINE; FLUVOXAMINE; NEUROLEPTIC AGENT; NOROLANZAPINE; OLANZAPINE; RISPERIDONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG EFFECT; DRUG INTOXICATION; DRUG MONITORING; DRUG POTENTIATION; DRUG TOLERABILITY; ENZYME INHIBITION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; METABOLIC INHIBITION; MOTOR DYSFUNCTION; NEGATIVE SYNDROME; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; STEADY STATE; TREATMENT OUTCOME;

EID: 0036785060     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200210000-00010     Document Type: Article

References (40)

1. Beasley CM Jr, Tollefson GD, Tran PV. Efficacy of olanzapine: an overview of pivotal clinical trials. J Clin Psychiatry 1997;58[Suppl 10]:7-12.
2. Bever KA, Perry PJ. Olanzapine: A serotonin-dopamine-receptor antagonist for antipsychotic therapy. Am J Health Syst Pharmacol 1998;55:1003-16.
3. Siris SG. Adjunctive medication in the maintenance treatment of schizophrenia and its conceptual implications. Br J Psychiatry 1993;163[Suppl 22]:66-78.
4. Silver H, Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add on double blind placebo controlled study. Biol Psychiatry 1992;31:698-704.
5. Silver H, Shmugliakov N. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia. J Clin Psychopharmacol 1998;18:208-11.
6. Silver H, Barash I, Aharon N, et al. Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study. Int Clin Psychopharmacol 2000;15:257-61.
7. Spina E, De Domenico P, Ruello C, et al. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int Clin Psychopharmacol 1994;9:281-5.
8. Goff DC, Midha KK, Sarid-Segal O, et al. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology (Berl) 1995;117;417-23.
9. Silver H. Fluvoxamine as an adjunctive agent in schizophrenia. CNS Drug Reviews 2001;7:283-304.
10. O'Connor M, Silver H. Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression. J Clin Psychopharmacol 1998;18:89-91.
11. Bogetto F, Bellino S, Vaschetto P, et al. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res 2000;96:91-8.
12. Weiss EL, Potenza MN, McDougle CJ, et al. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J Clin Psychiatry 1999;60:524-7.
13. Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiat 1996;57[Suppl]:12-25.
14. Hiemke C, Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000;85:11-28.
15. Kuo FJ, Lane HY, Chang WH. Extrapyramidal symptoms after addition of fluvoxamine to clozapine. J Clin Psychopharmacol 1998;53:483-4.
16. Bender C, Eap CB. Very high cytochrome P4501A2 activity and nonresponse to clozapine. Arch Gen Psychiatry 1998;55:1048-50.
17. Szegedi A, Wiesner J, Hiemke C. Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine. J Clin Psychopharmacol 1995;15:141-3.
18. Szegedi A, Anghelescu I, Wiesner J, et al. Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 1999;32:148-53.
19. Prior TI, Chue PS, Tibbo P, et al. Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol 1999;9:301-9.
20. Ring BJ, Catlow J, Lindsay TJ, et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 1996;276:658-66.
21. Kassahun K, Mattiuz E, Nyhart E Jr, et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos 1997;25:81-93.
22. Brøsen K, Skjelbo E, Rasmussen BB, et al. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45:1211-4.
23. Mäenpää J, Wrighton S, Bergstrom R, et al. Pharmacokinetic (PK) and pharmacodynamic interactions between fluvoxamine and olanzapine (abstract). Clin Pharmacol Ther 1997;61:225.
24. Weigmann H, Gerek S, Zeisig A, et al. Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 2001;23:410-3.
25. Lucas RA, Gilillan DJ, Bergstrom RF. A pharmacokinetic interaction between carbamazepine and olanzapine: observation on possible mechanism. Eur J Clin Pharmacol 1998;54:639-43.
26. Callaghan JT, Bergstrom RF, Ptak LR, et al. Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999;37:177-93.
27. de Jong J, Hoogenboom B, van Troostwijk LD, et al. Interaction of olanzapine with fluvoxamine. Psychopharmacology 2001;155:219-20.
28. Andreasen NC. Scale for the assessment of positive symptoms (SAPS). Iowa City: University of Iowa, 1984.
29. Andreasen NC. Scale for the assessment of negative symptoms (SANS). Iowa City: University of Iowa, 1983.
30. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;212[Suppl]:11-9.
31. Guy W. ECDU assessment manual for psychopharmacology. Rev ed. Dept. of Health Education and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health, 1976.
32. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res 1990;3:247-51.
33. Weigmann H, Härtter S, Maehrlein S, et al. Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column switching high performance liquid chromatography. J Chromatogr B 2001;759:63-71.
34. Härtter S, Wetzel H, Hiemke C. Automated determination of fluvoxamine in plasma by column-switching high-performance liquid chromatography. Clin Chem 1992;38:2082-6.
35. Wetzel H, Anghelescu I, Szegedi A, et al. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 1998;18:2-9.
36. Hiemke C, Weigmann H, Härtter S, et al. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 1994;14:279-81.
37. Jerling M, Lindstrøm L, Bondesson U, et al. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994;16:368-74.
38. Fabrazzo M, La Pia S, Notelone P, et al. Fluvoxamine increases plasma and urinary levels of clozapine and its major metabolites in a time- and dose-dependent manner. J Clin Psychopharmacology 2000;20:708-10.
39. Perry PJ, Lund BC, Sanger T, et al. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol 2001;21:14-20.
40. Robertson MD, McMullin MM. Olanzapine concentrations in clinical serum and postmortem blood specimens: when does therapeutic become toxic? J Forensic Sci 2000;45:418-21.